[{"id":"ce6cc088-a55e-4a98-8743-91177e066c1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01899599","created_at":"2021-01-18T08:32:51.601Z","updated_at":"2024-07-02T16:36:39.724Z","phase":"Phase 2","brief_title":"PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer","source_id_and_acronym":"NCT01899599","lead_sponsor":"Glycotope GmbH","biomarkers":" MUC16","pipe":" | ","alterations":" TA-MUC1 positive","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TA-MUC1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PankoMab-GEX (gatipotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 216","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 04/20/2017","primary_completion_date":" 04/20/2017","study_txt":" Completion: 07/28/2017","study_completion_date":" 07/28/2017","last_update_posted":"2020-10-22"}]